(MENAFN- GlobeNewsWire - Nasdaq) Data presented at Kidney Week 2025 showed single subcutaneous administration of megalin-STRIKERs resulted in increased excretion of disease-related solute levels ...

AI-powered vector design and preclinical validation mark the first step in a multi-phase program aimed at accelerating the path from discovery to clinical assessment in Alzheimer's disease. AUSTIN, TX ...

STAMFORD, Conn. (AP) — STAMFORD, Conn. (AP) — Pitney Bowes Inc. (PBI) on Wednesday reported earnings of $52 million in its third quarter. On a per-share basis, the Stamford, Connecticut-based company ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Bio-Gene Technology Ltd. ( (AU:BGT)) has ...

Oct 27 (Reuters) - BioMarin Pharmaceutical (BMRN.O), opens new tab said on Monday it plans to divest its gene therapy, a product once expected to be a blockbuster treatment for a type of rare bleeding ...

Shortly after taking the reins at BioMarin, CEO Alexander Hardy laid out three paths the company could take for its struggling hemophilia A gene therapy, Roctavian. A year after opting to shrink the ...

Shares of Pitney Bowes (PBI) were little changed in extended trading Wednesday after the company reported third-quarter results that came in line with Wall Street expectations for both profit and ...

Genetic engineers can design and assemble sophisticated gene circuits to program cells with new functions, but important signaling molecules can become diluted as these cells grow and divide, causing ...

Uniqure NV is regrouping after a surprise switcheroo by the havoc-beset U.S. FDA regarding phase I/II studies with AMT-130 vs. external control in Huntington’s disease (HD) – news of which pushed down ...

(MENAFN- EIN Presswire) EINPresswire/ -- Creative Bioarray, one of the top leading biotechnology products and service providers with cutting-edge technology that reveals research patterns in ...

PrisMN Phase 2 trial of budoprutug in Primary Membranous Nephropathy (pMN) initiated Phase 1 trial of budoprutug subcutaneous formulation initiated, with initial data expected in H1 2026 WELLESLEY ...